NCT05649579

Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid: a Multicenter Retrosepctive Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 146 (actual)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.

Conditions

• Bullous Pemphigoid

Interventions

Type	Name	Description
DRUG	Dupilumab	Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.

Timeline

• Start date: 2022-09-01
• Primary completion: 2022-12-31
• Completion: 2023-01-31
• First posted: 2022-12-14
• Last updated: 2023-12-04

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study